IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1239.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 19-Sep-2014
Cancer Cell
New cancer drug target involving lipid chemical messengers
More than half of human cancers have abnormally upregulated chemical signals related to lipid metabolism, yet how these signals are controlled during tumor formation is not fully understood. Researchers report that TIPE3, a newly described oncogenic protein, promotes cancer by targeting these pathways.
NIH/National Institute of Allergy and Infectious Diseases, NIH/National Institute of General Medical Sciences

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 19-Sep-2014
2D Materials
Graphene sensor tracks down cancer biomarkers
An ultrasensitive biosensor made from the wonder material graphene has been used to detect molecules that indicate an increased risk of developing cancer.

Contact: Michael Bishop
michael.bishop@iop.org
01-179-301-032
Institute of Physics

Public Release: 19-Sep-2014
ESMO 2014 Congress
Annals of Oncology
Patients with advanced, incurable cancer denied palliative care
Many patients with advanced, incurable cancer do not receive any palliative care, reveals new research to be presented later this month at the ESMO 2014 Congress in Madrid, Spain, Sept. 26-30. The findings are astonishing as they come at the same time as 15 new oncology centres in Europe, Canada, South America and Africa are being awarded the prestigious title of 'ESMO Designated Centre of Integrated Oncology and Palliative Care.'

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 19-Sep-2014
Magnetic Resonance in Medicine
A better way to track emerging cell therapies using MRIs
In a paper published Sept. 17 in the online journal Magnetic Resonance in Medicine, researchers at the University of California, San Diego School of Medicine, University of Pittsburgh and elsewhere describe the first human tests of using a perfluorocarbon tracer in combination with non-invasive magnetic resonance imaging to track therapeutic immune cells injected into patients with colorectal cancer.
National Institutes of Health

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 18-Sep-2014
Cell Reports
The war on leukemia: How the battle for cell production could be decisive
A key step in understanding the nature of the fight for superiority between mutated genes and normal genes could lead to new therapies to combat leukaemia, say researchers from the University of Birmingham and Newcastle University.
Leukaemia and Lymphoma Research, Cancer Research UK, Medical Research Council

Contact: Luke Harrison
l.harrison.1@bham.ac.uk
University of Birmingham

Public Release: 18-Sep-2014
Breast Cancer Research
The 'Angelina Effect' was not only immediate, but also long-lasting
Referrals for genetic counselling and testing for breast cancer risk more than doubled across the UK after actress Angelina Jolie announced in May last year that she tested positive for a BRCA1 gene mutation and underwent a double mastectomy. The rise in referrals continued through to October long after the announcement was made. This is according to research published in the journal Breast Cancer Research.

Contact: Shane Canning
shane.canning@biomedcentral.com
44-203-192-2243
BioMed Central

Public Release: 18-Sep-2014
Annals of Oncology
Experts issue plea for better research and education for advanced breast cancer
Breast cancer experts around the world have issued a plea to researchers, academics, drug companies, funders and advocates to carry out high quality research and clinical trials for advanced breast cancer, a disease which is almost always fatal and for which there are many unanswered questions. The plea is published in the latest international consensus guidelines for the management of advanced breast cancer, published simultaneously in the leading cancer journals The Breast and Annals of Oncology.

Contact: Emma Mason
wordmason@mac.com
European Society for Medical Oncology

Public Release: 18-Sep-2014
JAMA Internal Medicine
Professional recommendations against routine prostate cancer screening have little effect
The effect of guidelines recommending that elderly men should not be routinely screened for prostate cancer 'has been minimal at best,' according to a new study led by researchers at Henry Ford Hospital.

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System

Public Release: 18-Sep-2014
Immunity
LSU Health research discovers means to free immune system to destroy cancer
LSU Health New Orleans research has identified the crucial role an inflammatory protein known as Chop plays in the body's ability to fight cancer. Results demonstrate, for the first time, that Chop regulates the activity and accumulation of cells that suppress immune response against tumors. With Chop removed, the T-cells of the immune system mounted an effective attack on the cancer cells, revealing a new target for the development of immunotherapies to treat cancer.
National Institutes of Health

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center

Public Release: 18-Sep-2014
Clinical Cancer Research
Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma
A common Asian spice and cancer-hampering molecules show promise in slowing the progression of mesothelioma, a cancer of the lung's lining often linked to asbestos. Scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of curcumin, a derivative of the spice turmeric, and cancer-inhibiting peptides increase levels of a protein inhibitor known to combat the progression of this cancer. Their findings appear in Clinical Cancer Research.
Centers for Disease Control and Prevention, National Institutes of Health

Contact: Jeannette Spalding
jeannette.spalding@case.edu
216-368-3004
Case Western Reserve University

Public Release: 18-Sep-2014
American Journal of Physiology
Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds
Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy. Their work, performed in a mouse model of melanoma, found that combining exercise with chemotherapy shrunk tumors more than chemotherapy alone.
National Institutes of Health

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Public Release: 18-Sep-2014
Journal of the National Cancer Institute
Melanoma risk found to have genetic determinant
A leading Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, co-authored a paper published today in the Journal of the National Cancer Institute that proves longer telomeres increase the risk of melanoma.
Cancer Research UK, National Institutes of Health

Contact: Robin Dutcher
robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth

Public Release: 17-Sep-2014
Menopause
NAMS issues first comprehensive recommendations on care of women at menopause and beyond
The North American Menopause Society has published its key, evidence-based recommendations for the comprehensive care of midlife women -- on everything from hot flashes to heart disease. This is the first, comprehensive set of evidence-based recommendations for the care of midlife women freely available to all clinicians who care for women at this stage of life.

Contact: Eileen Petridis
epetridis@fallscommunications.com
216-696-0229
The North American Menopause Society (NAMS)

Public Release: 17-Sep-2014
ASTRO's 56th Annual Meeting
Many throat cancer patients can skip neck surgery
A new study shows that patients with human papillomavirus (HPV) -- the same virus associated with both cervical and head and neck cancer -- positive oropharyngeal cancer see significantly higher rates of complete response on a post-radiation neck dissection than those with HPV-negative oropharyngeal cancer. Fox Chase Cancer Center researchers presented the findings at the American Society for Radiation Oncology's 56th Annual Meeting on Wednesday, Sept. 17.

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center

Public Release: 17-Sep-2014
ASTRO's 56th Annual Meeting
Targeted radiation, drug therapy combo less toxic for recurrent head, neck cancers
Patients with a recurrence of head and neck cancer who have previously received radiation treatment can be treated more quickly, safely and with fewer side effects with high doses of targeted radiation known as Stereotactic Body Radiation Therapy in combination with a drug that also carefully targets cancerous tumors. These findings from a UPMC CancerCenter study were presented today at the American Society of Radiation Oncology annual meeting in San Francisco.

Contact: Jennifer C. Yates
YatesJC@upmc.edu
412-647-9966
University of Pittsburgh Schools of the Health Sciences

Public Release: 17-Sep-2014
Science Translational Medicine
Blood test could identify when cancer treatment has become detrimental
Some treatments for prostate cancer, while initially effective at controlling the disease, not only stop working over time but actually start driving tumour growth, a major new study shows.
Prostate Cancer UK, Movember Foundation, Cancer Research UK

Contact: Henry French
henry.french@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 17-Sep-2014
Maturitas
Elsevier journal Maturitas publishes position statement on breast cancer screening
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of a position statement by the European Menopause and Andropause Society in the journal Maturitas on the topic of breast cancer screening.

Contact: Greyling Peoples
g.peoples@elsevier.com
31-204-853-323
Elsevier

Public Release: 17-Sep-2014
Journal of Clinical Pathology
Wild berry extract may strengthen effectiveness of pancreatic cancer drug
A wild berry native to North America may strengthen the effectiveness of a chemotherapy drug commonly used to treat pancreatic cancer, reveals research published online in the Journal of Clinical Pathology.
Ministry of Higher Education - Malaysia, Have a Chance Inc.

Contact: Becky Attwood
r.attwood@soton.ac.uk
University of Southampton

Public Release: 17-Sep-2014
Cancer Research
New non-invasive technique could revolutionize the imaging of metastatic cancer
In preclinical animal models of metastatic prostate cancer, scientists at Virginia Commonwealth University Massey Cancer Center, VCU Institute of Molecular Medicine and Johns Hopkins Medical Institutions have provided proof-of-principle of a new molecular imaging approach that could revolutionize doctors' ability to see tumors that have metastasized to other sites in the body, including the bones.
NIH/National Cancer Institute, Prostate Cancer Foundation, Patrick C. Walsh Foundation, National Foundation for Cancer Research

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University

Public Release: 17-Sep-2014
Scientific Reports
Researchers examine role of hormone in response to ovarian cancer treatment
Researchers at Women & Infants Hospital of Rhode Island recently published the results of an investigation into how we might better tailor therapy for ovarian cancer.

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Women & Infants Hospital

Public Release: 17-Sep-2014
Nature Genetics
Large study reveals new genetic variants that raise risk for prostate cancer
In an analysis of genetic information among more than 87,000 men, a global team of scientists says it has found 23 new genetic variants -- common differences in the genetic code -- that increase a man's risk for prostate cancer. The so-called 'meta-analysis,' believed to be the largest of its kind, has revealed once hidden mutations among men in a broad array of ethnic groups comprising men of European, African, Japanese and Latino ancestry.
US Department of Defense, NIH/National Cancer Institute, Cancer Research UK, Prostate Cancer UK, EU, Patrick Henry, P. Kevin Jaffe, and Peter Jay Sharpe Foundation

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 17-Sep-2014
Nature Genetics
Moffitt researchers help lead efforts to find new genetic links to prostate cancer
Researchers at Moffitt Cancer Center, including Center Director Thomas A. Sellers, Ph.D., M.P.H., Jong Park, Ph.D. and Hui-Yi Lin, Ph.D., have discovered 23 new regions of the genome that influence the risk for developing prostate cancer, according to a study published Sept. 14 in Nature Genetics.

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 17-Sep-2014
Journal of Biological Chemistry
Abnormal properties of cancer protein revealed in fly eyes
Mutations in the human retinoblastoma protein gene are a leading cause of eye cancer. Now, Michigan State University scientists have turned to fruit fly eyes to unlock the secrets of this important cancer gene.

Contact: Layne Cameron
layne.cameron@cabs.msu.edu
517-353-8819
Michigan State University

Public Release: 17-Sep-2014
Oncotarget
Five genes to predict colorectal cancer relapses
Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, led by David Garcia-Molleví have identified five genes differentially expressed in normal accompanying cells in colorectal tumors. Analysis of these genes could be used to classify colorectal tumors, predict the evolution of the patient and thus take appropriate clinical decisions to prevent relapses.
Spanish Government

Contact: Arantxa Mena
amena@idibell.cat
34-932-607-282
IDIBELL-Bellvitge Biomedical Research Institute

Public Release: 17-Sep-2014
Journal of the National Cancer Institute
Chromosome buffers hold key to better melanoma understanding
Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma -- the deadliest form of skin cancer -- according to new research from the University of Leeds.
Cancer Research UK

Contact: Ben Jones
B.P.Jones@leeds.ac.uk
44-011-334-38059
University of Leeds

Showing releases 1-25 out of 1239.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases

     

Featured Multimedia

 

EurekAlert!